| Autor: |
Farooqi AA; Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 44000, Pakistan., Rakhmetova VS; Department Internal Diseases, Medical University of Astana, Astana 010000, Kazakhstan., Kapanova G; Al-Farabi Kazakh National University, 71 Al-Farabi Ave, Almaty 050040, Kazakhstan.; Scientific Center of Anti-Infectious Drugs, 75 Al-Farabi Ave, Almaty 050040, Kazakhstan., Tashenova G; Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan., Tulebayeva A; Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan., Akhenbekova A; Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan., Ibekenov O; Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.; Syzganov National Scientific Center of Surgery, Almaty 050040, Kazakhstan., Turgambayeva A; Department of Public Health and Management, NJSC Astana Medical University, Astana 010000, Kazakhstan., Xu B; Food Science and Technology Program, Department of Life Sciences, BNU-HKBU United International College, Zhuhai 519087, China. |
| Abstrakt: |
The renaissance of research into natural products has unequivocally and paradigmatically shifted our knowledge about the significant role of natural products in cancer chemoprevention. Bufalin is a pharmacologically active molecule isolated from the skin of the toad Bufo gargarizans or Bufo melanostictus . Bufalin has characteristically unique properties to regulate multiple molecular targets and can be used to harness multi-targeted therapeutic regimes against different cancers. There is burgeoning evidence related to functional roles of signaling cascades in carcinogenesis and metastasis. Bufalin has been reported to regulate pleiotropically a myriad of signal transduction cascades in various cancers. Importantly, bufalin mechanistically regulated JAK/STAT, Wnt/β-Catenin, mTOR, TRAIL/TRAIL-R, EGFR, and c-MET pathways. Furthermore, bufalin-mediated modulation of non-coding RNAs in different cancers has also started to gain tremendous momentum. Similarly, bufalin-mediated targeting of tumor microenvironments and tumor macrophages is an area of exciting research and we have only started to scratch the surface of the complicated nature of molecular oncology. Cell culture studies and animal models provide proof-of-concept for the impetus role of bufalin in the inhibition of carcinogenesis and metastasis. Bufalin-related clinical studies are insufficient and interdisciplinary researchers require detailed analysis of the existing knowledge gaps. |
